Unlearn’s First Ever Webinar Series, Powering Clinical Research with AI, is available On-Demand

This year, Unlearn launched our first-ever, 3 part webinar series, Powering Clinical Research with AI. These webinars served as a unique opportunity to educate subject matter experts and industry leaders about the transformative potential of AI in clinical research. Now, more than ever, it is critical to embrace innovation to accelerate the clinical trial process, so that new treatments are made available to patients sooner who urgently need them. Our series provides a comprehensive look at how Digital Twins, or AI-generated control outcomes for trial participants, are created, and how this technology enables smaller, more efficient trials. Experts also share regulatory perspectives, forecasts, and strategies for AI-based drug development tools like Digital Twins. All 3 webinars are available to watch, on-demand, below. We encourage you to reach out to partnerships@unlearn.ai to discuss how Digital Twins can accelerate your clinical research, or if you have any questions about our novel approach. 


Part 1: AI, Digital Twins, and the Future of Clinical Research

In our first webinar, our Founder & CEO, Charles Fisher, explains how Digital Twins are created, and how they can be incorporated into trials to increase statistical power, accelerate trial timelines, and enable patient level insights. 


Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins

Our second webinar provides an overview of specific use cases for Digital Twins, where two of our founders walk through how novel trial designs with Digital Twins enable smaller trials that maintain their power.


Part 3:  Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape

In the third installment, Charles Fisher of Unlearn, Diane Shoda of Greyscaling LLC, and Wade Ackerman of Covington & Burling LLP lead a panel discussion on the regulatory landscape and share expert perspectives on the future of AI-based drug development tools like Digital Twins.


Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

How will AI transform the future of medicine?

White Papers

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs

Both methods reduce control arm sizes, but only digital twins control for bias.
A Phase 2 study on crenezumab in mild-to-moderate AD was used to retrospectively assess the validity of Unlearn's approach for AD clinical trials.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.